Zobrazeno 61 - 70
of 110
pro vyhledávání: '"Kenneth F. Grossmann"'
Autor:
Hung T. Khong, Richard S. Ungerleider, Sanjiv S. Agarwala, Robert H.I. Andtbacka, Adil Daud, Kenneth F. Grossmann, Merrick I. Ross, John T. Vetto, Matthew H. Taylor, Maki Tanaka, Rogerio I. Neves
Publikováno v:
Journal of Clinical Oncology. 35:9510-9510
9510 Background: HF10 is a bioselected replication-competent oncolytic virus derived from HSV-1. Herein, we report the safety and efficacy data of HF10 + ipilimumab (ipi) combination treatment in a Phase II trial in melanoma. Methods: Key entry crite
Autor:
Michael S. Gordon, Samuel C. Blackman, A. Benjamin Suttle, Sunil Sharma, Lauren E. Richards-Peterson, Manish R. Patel, Hendrik Tobias Arkenau, Jeffrey R. Infante, Patricia M. Lorusso, Mark R. Middleton, Kari Kendra, Jeff Botbyl, Shubham Pant, Kenneth F. Grossmann, Daniele Ouellet, Gursel Aktan, Stanley W. Carson
Publikováno v:
Journal of clinical pharmacology. 55(4)
The induction of CYP2C9 by dabrafenib using S-warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib pharmacokinetics were evaluated in patients with BRAF V600 mutation-positive tumo
Autor:
April K.S. Salama, C. Robert, Joel Jiang, Montaser Shaheen, David R. Minor, Paul Gagnier, Anna C. Pavlick, Christine Horak, Patrick A. Ott, Jedd D. Wolchok, F.S. Hodi, David F. McDermott, Nicolas Meyer, Matthew H. Taylor, Jeffrey K. Giguere, Kenneth F. Grossmann, Marc S. Ernstoff, Michael A. Postow, Jason Chesney, Gerald P. Linette, Sanjiv S. Agarwala
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 143:S214
Introduction Les resultats d’essais cliniques ont montre une amelioration significative du taux de reponse objective et de la survie sans progression (SSP) avec nivolumab (NIVO ; un anticorps anti-PD-1) plus ipilimumab (IPI ; un anticorps anti-CTLA
Autor:
Merrick I. Ross, Rogerio I. Neves, Sanjiv S. Agarwala, Matthew H. Taylor, Richard S. Ungerleider, Robert H.I. Andtbacka, Kenneth F. Grossmann, Adil Daud, Hung Thieu Khong, Maki Tanaka, John T. Vetto, S. Welden
Publikováno v:
Annals of Oncology. 27:vi393
Autor:
Joan Van Atta, Neeraj Agarwal, Jeffrey A. Gilreath, Laura Alwan, Daniel S. Sageser, Kenneth F. Grossmann
Publikováno v:
Targeted oncology. 9(1)
We compared acute toxicity, drug exposure, in-hospital mortality, and inpatient length of stay between two currently recommended dosing protocols (from the National Comprehensive Cancer Network Guidelines) of high-dose interleukin-2 (IL-2) treatment
Autor:
Kenneth F. Grossmann, James W. Clancy, Dean Y. Li, Sheryl R. Tripp, Aaron Rogers, Alanna Sedgwick, Shannon J. Odelberg, Allie H. Grossmann, Lise K. Sorensen, Jae Hyuk Yoo, Kirk R. Thomas, Crislyn D'Souza-Schorey, Kirill Ostanin, Zongzhong Tong
Publikováno v:
Science Signaling. 6
β-Catenin has a dual function in cells: fortifying cadherin-based adhesion at the plasma membrane and activating transcription in the nucleus. We found that in melanoma cells, WNT5A stimulated the disruption of N-cadherin and β-catenin complexes by
Autor:
Montaser Shaheen, Sanjiv S. Agarwala, Jason Chesney, Jeffrey K. Giguere, F. Stephen Hodi, Gerald P. Linette, David R. Minor, Michael A. Postow, Anna C. Pavlick, Kenneth F. Grossmann, Caroline Robert, Nicolas Meyer, Paul Gagnier, Matthew H. Taylor, April K.S. Salama, David F. McDermott, Marc S. Ernstoff, Christine Horak, Patrick A. Ott, Joel Jiang, Jedd D. Wolchok
Publikováno v:
Cancer Research. 76:CT002-CT002
Background: This phase II trial (CheckMate 069) demonstrated a statistically significant improvement in objective response rate (ORR) and progression-free survival (PFS) with the combination of NIVO+IPI vs. IPI alone in treatment-naïve patients (pts
Autor:
James Moon, John M. Kirkwood, Kenneth F. Grossmann, Megan Othus, Antoni Ribas, Vernon K. Sondak, Ahmad A. Tarhini, Sapna Pradyuman Patel
Publikováno v:
Cancer Research. 76:CT125-CT125
Background: Adjuvant therapy for melanoma has centered on high dose interferon for now almost 20 years. Recently, the FDA approved ipilimumab dosed at 10 mg/kg (10/kg ipi) for use in high risk resected melanoma. Though these two treatment options are
Autor:
Sanjiv S. Agarwala, John T. Vetto, Rogerio I. Neves, Robert H.I. Andtbacka, Matthew H. Taylor, Richard S. Ungerleider, Adil Daud, Merrick I. Ross, Maki Tanaka, Aislyn D. Boran, Hung T. Khong, Kenneth F. Grossmann
Publikováno v:
Journal of Clinical Oncology. 34:9543-9543
9543Background: HF10 is a replication-competent oncolytic virus derived from HSV-1. We report on preliminary safety data and antitumor activity of HF10 + ipilimumab (ipi) combination in an ongoing Phase 2 trial in melanoma. Methods: Key entry criteri
Autor:
Michael S. Gordon, Kenneth F. Grossmann, Lihua Tang, Jason D. Lickliter, Noelia Nebot, Jason C. Chandler, Stanley W. Carson, Annie St-Pierre, Bijoyesh Mookerjee, H.-T. Arkenau, Jeffrey R. Infante, Andrew Weickhardt, John Sarantopoulos
Publikováno v:
Journal of Clinical Oncology. 34:e14119-e14119
e14119Background: Dabrafenib (DAB) is a BRAF inhibitor approved at a dose of 150 mg twice daily (BID) for treating unresectable or metastatic BRAF V600E/K–mutant melanoma with or without trametinib...